BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Danco Laboratories Alerts Doctors To Five Deaths


10/19/2005 5:10:48 PM

Five women who took the abortion pill RU-486 have died from bacterial infections since its U.S. introduction nearly five years ago, the manufacturer reported on Monday. "No causal relationship between these events" has been established with the drug, also known as Mifeprex or mifepristone, maker Danco Laboratories LLC said. "Childbirth, menstruation and abortion, whether spontaneous, surgical or medical, all create conditions that can result in serious and sometimes fatal infection, and there is no evidence that Mifeprex and misoprostol present a special risk of infection," the company said in a statement. Misoprostol is a drug that women must take two days after Mifeprex to complete the abortion. Danco said it was sending a letter to alert physicians about the cases and updating warning information on the drug's label. Mifeprex already carries a warning about the possibility that women who take the drug could experience serious and sometimes fatal infections. The company is updating the label to give physicians more information to help them spot the problem, Danco spokeswoman Cynthia Summers said.

Read at Reuters

Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES